$heff's $tation of $tocks & $olid DD

[$heff]

DEPO..$6.47 The ADCOM notes were pretty boring. The efficacy is avg & the safety is better than avg. FDA tends to lean more towards safety over efficacy in these ADCOM mtngs from what I have seen. Don't currently plan on trading this through the ADCOM. May trade after I hear of the panel decision. Too many trades to look at through May.

DRAFT TOPICS FOR DISCUSSION (Pg. 7)
Committee members are asked to reflect upon the following issues as they review the
information provided in this Background Document.
Issues for discussion include the following:
• Based on the Applicant’s pre-specified analyses, is there sufficient evidence to
conclude that gabapentin is effective in treating moderate to severe vasomotor
symptoms (VMS) due to menopause?
• Is the overall risk/benefit profile of gabapentin acceptable to support approval of
this product for the proposed indication?


Message in reply to:

DEPO..$6.34 FDA docs out http://stks.co/q3vg. The stock is trading steady after the release. The ADCOM is on Monday.